 These advances allowed for the specific targeting of tumors both in vitro and in vivo.Initial research on malignant neoplasms found mAb therapy of limited and generally short-lived success with blood malignancies.Treatment also had to be tailored to each individual patient, which was impracticable in routine clinical settings.